Z
Zhuo-Xun Wu
Researcher at St. John's University
Publications - 51
Citations - 971
Zhuo-Xun Wu is an academic researcher from St. John's University. The author has contributed to research in topics: Multiple drug resistance & Biology. The author has an hindex of 12, co-authored 32 publications receiving 329 citations.
Papers
More filters
Journal ArticleDOI
Microbiota in health and diseases
Kaijian Hou,Zhuo-Xun Wu,Xuan-Yu Chen,Jing-Quan Wang,Dongya Zhang,Chuan Xiao,Dan Zhu,Jagadish B. Koya,Liuya Wei,Jilin Li,Zhe S Chen +10 more
TL;DR: The role of microbiota in health and diseases is highlighted by numerous studies since its discovery as mentioned in this paper , which can lead to dysregulation of bodily functions and diseases including cardiovascular diseases (CVDs), cancers, respiratory diseases, etc.
Journal ArticleDOI
The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer
Lei Zhang,Lei Zhang,Yi-Dong Li,Qianchao Wang,Zhuo Chen,Xiaoyun Li,Xiaoyun Li,Zhuo-Xun Wu,Chaohua Hu,Dan Liao,Dan Liao,Wei Zhang,Wei Zhang,Zhe-Sheng Chen +13 more
TL;DR: The reversal of the dual functions of ABC-transporter-mediated and AKT-activation-enhanced MDR through the inhibition or knockout of PI3K 110α or 110β promises to improve current strategies based on combined drug treatments to overcome MDR challenges.
Journal ArticleDOI
Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications.
Huibin Song,Dongcheng Liu,Shaowei Dong,Leli Zeng,Leli Zeng,Zhuo-Xun Wu,Pan Zhao,Litu Zhang,Zhe-Sheng Chen,Chang Zou +9 more
TL;DR: The recent progress in overcoming cancer drug resistance is summarized in three novel aspects: mRNA modification, which includes alternative splicing, A-to-I modification and mRNA methylation, and posttranslational modification on molecules, which encompasses drug inactivation/efflux, drug target modifications, DNA damage repair, cell death resistance, EMT, and metastasis.
Journal ArticleDOI
Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19.
Zi-Ning Lei,Zhuo-Xun Wu,Shaowei Dong,Shaowei Dong,Dong-Hua Yang,Litu Zhang,Zunfu Ke,Chang Zou,Chang Zou,Zhe-Sheng Chen +9 more
TL;DR: The applications and mechanisms of action of CQ and HCQ in their conventional fields of anti-malaria and anti-rheumatism, as well as their repurposing prospects in anti-virus are reviewed.
Journal ArticleDOI
Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells.
Zhuo-Xun Wu,Qiu-Xu Teng,Chao-Yun Cai,Jing-Quan Wang,Zi-Ning Lei,Yuqi Yang,Ying-Fang Fan,Jianye Zhang,Jun Li,Jun Li,Zhe-Sheng Chen +10 more
TL;DR: A potential chemotherapeutic strategy of co-administrating tepotinib with other conventional chemotherAPEutic agents to overcome MDR and improve therapeutic effect is provided.